CHPA Agenda 2014: Monograph Reform, NSURE Progress
This article was originally published in The Tan Sheet
The Consumer Healthcare Products Association plans to tackle big tasks in 2014, including working with FDA to improve the monograph system, move the new Rx-to-OTC switch paradigm forward and determine quality metrics to help FDA better target inspections. The trade group also is looking for ways to ease pricing pressures and ensure quality does not suffer.
You may also be interested in...
Reps. Dingell and Whitfield ask for FDA’s assistance on legislation they are writing to expedite the agency’s review of additional sunscreen ingredients. CDER Director Woodcock pledges FDA help, but explains the agency’s OTC ingredient reviews are “backlogged.”
The firm’s Chattem division will bring the 24-hour nasal allergy spray to market in the spring of 2014.
CHPA urges FDA not to wait until it publishes the final internal analgesics, antipyretic and anti-rheumatic monograph before allowing manufacturers to label acetaminophen products with dosing information for children 6 months to 2 years old. In a citizen petition, the trade group proposes FDA publish a statement of enforcement policy expressly permitting the use of a standardized age- and weigh-based dosing chart.